Equity Profile

TEVA

Teva Pharmaceutical Industries Limited

Health CarePharmaceuticals$39.8B

Apr29Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Teva Pharmaceutical Beats on EPS, Stock Up 0.00%

Metric	Actual	Expected	Surprise
EPS	$0.53	$0.46	+8.83%
Revenue	N/A	$3.8B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Teva Pharmaceutical Beats on EPS, Stock Up 0.00%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.53	$0.46	+8.83%
Revenue	N/A	$3.8B	N/A

Management Commentary

Tone: Cautiously Optimistic

Management expressed cautious optimism about future performance, focusing on operational improvements. They acknowledged ongoing market challenges but are committed to enhancing product availability.

Management highlighted ongoing efforts to streamline operations.

They emphasized a focus on improving product availability.

The team remains committed to addressing market challenges.

What It Means

Teva Pharmaceutical's earnings report shows a positive surprise in EPS, which may indicate better-than-expected cost management or operational efficiency. However, the stock reaction remained flat, suggesting investors may be waiting for more clarity on revenue performance and future guidance. The lack of revenue data and guidance could lead to uncertainty in the stock's near-term outlook.

Company Snapshot

Teva Pharmaceutical Industries Limited is a global leader in the pharmaceutical sector, primarily known for its generic and specialty medications. With a market cap of $36 billion, Teva plays a crucial role in providing affordable healthcare solutions, especially in a time when healthcare costs are a significant concern for consumers and governments alike.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Teva is managing its costs and revenues.

0.46

Revenue

Total revenue will reflect the company's sales performance and market demand for its products.

3.8B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

In Q4 2025, Teva reported an EPS of $0.96, significantly beating estimates of $0.63, which led to a positive market reaction. The company's strong performance in the previous quarter may set a favorable tone for this upcoming earnings report.

Management Promises & Guidance

Continued focus on cost management and operational efficiency.
Commitment to expanding its product pipeline.
Plans to enhance market presence in emerging economies.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Teva's upcoming earnings, expecting a solid performance based on previous quarters' results. The consensus EPS estimate is $0.46, indicating confidence in the company's ability to maintain profitability.

Bull Case

If Teva exceeds the EPS estimate, it would reinforce investor confidence and could lead to a significant stock price increase, similar to past performance where the stock rose after earnings beats.

Bear Case

Conversely, if Teva fails to meet expectations, especially after a strong previous quarter, it could lead to a sharp decline in stock price, reflecting investor disappointment.

Key Metrics to Watch

EPS

0.46

Earnings per share is a key indicator of profitability and will show how well Teva is managing its costs and revenues.

Revenue

3.8B

Total revenue will reflect the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Teva's EPS exceed the consensus estimate of $0.46?

A beat on EPS would affirm the company's operational strength and could lead to a positive market reaction.

How will revenue compare to the consensus estimate of $3.8 billion?

Revenue performance is critical for assessing market demand and the overall health of Teva's business.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Teva's ability to capitalize on emerging market opportunities, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Teva's recent product launches may not be fully reflected in current revenue estimates.

The company's cost management strategies could lead to better-than-expected margins.

Options pricing suggests a higher volatility expectation, indicating that traders may anticipate significant news.

Key Risk

If revenue comes in above $4.0 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is under scrutiny as investors look for signs of sustained growth and profitability after a strong previous quarter.

Bull Confirmed If

An EPS of $0.52 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.41 would support the bear case, suggesting potential challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±11.18%

Historical Avg

±9.0%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±12.6% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.7%

30d HV

32.8%

Calls (278K)P/C Ratio: 1.87Puts (916K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests the stock could rise by around 2.64%, confirming the company's positive trajectory.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted response as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 12.83% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into market demand trends, especially in emerging markets.
4Guidance on future earnings expectations and any changes to the product pipeline.
5Responses to questions about competitive pressures in the pharmaceutical industry.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Teva is managing its costs and revenues.

0.46

Revenue

Total revenue will reflect the company's sales performance and market demand for its products.

3.8B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+15.61%

Avg Stock Reaction

+3.79%

Last Quarter Recap

Management Promises & Guidance

Continued focus on cost management and operational efficiency.
Commitment to expanding its product pipeline.
Plans to enhance market presence in emerging economies.

Expectations

Wall Street Expectations

Bull Case

If Teva exceeds the EPS estimate, it would reinforce investor confidence and could lead to a significant stock price increase, similar to past performance where the stock rose after earnings beats.

Bear Case

Conversely, if Teva fails to meet expectations, especially after a strong previous quarter, it could lead to a sharp decline in stock price, reflecting investor disappointment.

Key Metrics to Watch

EPS

0.46

Earnings per share is a key indicator of profitability and will show how well Teva is managing its costs and revenues.

Revenue

3.8B

Total revenue will reflect the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Teva's EPS exceed the consensus estimate of $0.46?

A beat on EPS would affirm the company's operational strength and could lead to a positive market reaction.

How will revenue compare to the consensus estimate of $3.8 billion?

Revenue performance is critical for assessing market demand and the overall health of Teva's business.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Teva's ability to capitalize on emerging market opportunities, which could drive stronger-than-expected revenue growth.

Supporting Evidence

Teva's recent product launches may not be fully reflected in current revenue estimates.

The company's cost management strategies could lead to better-than-expected margins.

Options pricing suggests a higher volatility expectation, indicating that traders may anticipate significant news.

Key Risk

If revenue comes in above $4.0 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is under scrutiny as investors look for signs of sustained growth and profitability after a strong previous quarter.

Bull Confirmed If

An EPS of $0.52 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.41 would support the bear case, suggesting potential challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±11.18%

Historical Avg

±9.0%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±12.6% while TEVA has averaged ±9.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.7%

30d HV

32.8%

Calls (278K)P/C Ratio: 1.87Puts (916K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Teva beats expectations, history suggests the stock could rise by around 2.64%, confirming the company's positive trajectory.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted response as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 12.83% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into market demand trends, especially in emerging markets.
4Guidance on future earnings expectations and any changes to the product pipeline.
5Responses to questions about competitive pressures in the pharmaceutical industry.